Loading...
Loading...
SLNO| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 598.0K |
| Gross Profit | -598.0K |
| Operating Expense | 8,310.0K |
| Operating I/L | -8,623.0K |
| Other Income/Expense | -312.0K |
| Interest Income | 147.0K |
| Pretax | -8,475.0K |
| Income Tax Expense | 165.0K |
| Net Income/Loss | -8,475.0K |
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel therapeutics for rare diseases. Its primary revenue-generating product is Diazoxide Choline Controlled-Release, an oral tablet designed for the treatment of Prader-Willi Syndrome. The company's focus is on advancing this product through an ongoing Phase III clinical development program, aiming to bring it to market as a once-daily treatment option for patients with this rare condition.
